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Streptococcus agalactiae or group B streptococcus (GBS) remains 
a significant cause of neonatal sepsis, responsible for early-onset 
disease (EOD) (<7 days of age) and late-onset disease (LOD) (7 - 
89 days of age).[1] The incidence of EOD has declined significantly 
in countries where universal screening of pregnant women for GBS 
colonisation is undertaken between 34 and 37 weeks of gestational 
age and intrapartum antibiotic prophylaxis (IAP) during labour is 
provided to colonised women.[2] 
Penicillin is the drug of choice for IAP and for the treatment 
of GBS-EOD and GBS-LOD. Women with a history of penicillin 
allergy, but at low risk for penicillin anaphylaxis, should receive 
alternative treatment with a cephalosporin such as cefazolin instead 
of erythromycin or clindamycin.[2] This is due to an increasing 
resistance of GBS to clindamycin and erythromycin. Reported rates 
of resistance of GBS to erythromycin range from 25% to 32% and 
resistance to clindamycin from 13% to 20%.[2] Vancomycin is an 
appropriate alternative for patients with a history of anaphylaxis to 
penicillin and when an isolate is resistant to clindamycin.
An effective GBS vaccine may prevent a broad scope of GBS-
associated diseases, such as GBS-EOD, GBS-LOD, spontaneous 
abortion, stillbirth and maternal bacteraemia.[2,3] One approach of 
vaccine development is to target the capsular polysaccharide (CPS) of 
GBS. GBS serological grouping is based on the polysaccharide capsule. 
It is therefore imperative to determine the GBS serotypes of various 
geographical regions to develop an inclusive multivalent CPS vaccine. 
There are currently 10 serotypes, i.e. Ia, Ib and II - IX. The 
distribution of the 5 most common GBS serotypes in South Africa 
(SA) that cause invasive disease is III (55.4%), Ia (28.2%), V (7.9%), 
II (3.6%) and Ib (3.4%), and II (5%).[4] This is similar to the 
global distribution.[5] GBS isolates (7 - 30%) are serologically non-
serotypeable.[6] In a study conducted at prenatal community clinics 
in Soweto, SA, researchers looked at the GBS serotype distribution 
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Background. Streptococcus agalactiae or group B streptococcus (GBS) is a significant cause of neonatal sepsis. Intrapartum antibiotic 
prophylaxis is recommended for pregnant women identified to be rectovaginally colonised between 34 and 37 weeks’ gestational age to 
decrease the risk of invasive disease in their newborns. An effective multivalent GBS vaccine may prevent a broader scope of GBS-associated 
diseases, such as GBS early-onset disease, GBS late-onset disease, spontaneous abortion, stillbirth and maternal bacteraemia. Serotype 
distribution of GBS isolates is essential to determine the efficacy of such a vaccine. 
Objectives. To investigate serotype distribution and antimicrobial susceptibility patterns of GBS isolates cultured from rectovaginal 
specimens during pregnancy. 
Methods. Sixty-nine archived maternal colonising isolates were tested against penicillin, erythromycin, clindamycin, vancomycin and 
levofloxacin. Minimum inhibitory concentration testing was performed using the ETEST method. Serotyping was performed by the latex 
agglutination method.
Results. The most common serotypes detected were Ia (54%), III (20%), V (16%), II (6%), IV (2%) and Ib (1%). All isolates were fully 
susceptible to penicillin, vancomycin and levofloxacin. Eight (11%) and 50 (56%) isolates showed intermediate resistance to erythromycin 
and clindamycin, respectively, and 1 isolate was resistant to erythromycin. The macrolide-lincosamide-streptogramin B (MLSB) phenomenon 
was noted in 3 (4%) of the isolates. 
Conclusions. GBS-colonising isolates remain susceptible to penicillin, which remains the drug of choice for intrapartum antibiotic 
prophylaxis and treatment of invasive disease in newborns. Macrolides should only be used if clinically indicated due to the high prevalence 
of intermediate resistance. A pentavalent GBS vaccine currently in phase I trials should provide coverage for 97% of the isolates identified 
in this study. 
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rate in colonised mothers, who were swabbed at 5 - 6-week intervals 
from gestational age 20 - 25 weeks to 37 - 40 weeks. The serotype 
distribution in that study was Ia (36.2 - 41.4%), III (31.3 - 34.9%), 
V (10.3 - 15.6%), II (7.2 - 7.5%), Ib (3.5 - 4.6%), IV (2.0 - 4.0%) and 
IX (0.0 - 3.3%).[7] In a recent Canadian study, the most common 
serotypes seen in maternal colonising GBS strains were III (25%), Ia 
(23%) or V (19%).[8] The next most common serotypes were II (13%) 
and Ib (9%).[8]
The purpose of this laboratory-based observational study was 
to determine the serotype distribution of rectovaginal colonising 
isolates from pregnant women in the Pretoria area, SA, and the anti-
microbial susceptibility patterns thereof. This serotype distribution, 
in particular, would be useful to determine the local relevance of a 
global vaccine, should it be introduced in SA.
Methods
We examined 69 archived GBS isolates from a study done in 2014, 
which investigated the prevalence of GBS colonisation in pregnant 
women between 26 and 37 weeks’ gestation.[9] In that study, 284 preg-
nant women were enrolled from an antenatal clinic and tested for 
GBS colonisation by Xpert (Cepheid, USA) GBS and culture. The 
colonisation rate was 25% by culture and 24% by Xpert GBS.[7] The 
GBS isolates from that study were stored in trypticase soy broth with 
5% glycerol.
Microbiology testing for this study was performed at the Tshwane 
Academic Division, Microbiology Laboratory, National Health 
Laboratory Service (NHLS). The stored isolates were subcultured on 
5% sheep blood agar and incubated for 24 hours in 5% CO2. Beta-
haemolytic colonies were then lawned onto Mueller-Hinton agar, 
with 5% sheep blood for minimum inhibitory concentration (MIC) 
testing using ETEST (bioMérieux, France) strips. Five antibiotics 
were tested for each isolate, i.e. penicillin, vancomycin, erythromycin, 
clindamycin and levofloxacin. Plates were incubated for 24 hours in 
5% CO2 at 35 - 37
oC. The MICs were determined using the latest 
Clinical and Laboratory Standards Institute (CLSI) breakpoints 
(2015). The MICs of GBS isolates that tested non-susceptible or 
resistant for any of the 5 antibiotics were repeated and the results 
confirmed. Furthermore, 2 observers read the MIC values of all the 
isolates to minimise inter-observer variability.
As per CLSI guidelines for beta-haemolytic streptococci, macrolide-
lincosamide-streptogramin B (MLSB) testing was performed on each 
isolate to test for inducible clindamycin resistance. The isolates were 
plated on Mueller-Hinton plus 5% sheep blood agar, after which 
erythromycin and clindamycin discs were placed next to each other, 
12 mm apart. The plates were incubated at 35 - 37oC in 5% CO2 for 
18 - 24 hours. A ‘D-zone’ on the side of the clindamycin disc facing 
the erythromycin disc was taken as positive for the MLSB resistance 
phenotype.
Serotyping of the isolates was conducted at the Respiratory and 
Meningeal Pathogens Research Unit (RMPRU), University of the 
Witwatersrand, Johannesburg, SA. Serotyping was performed using 
the latex agglutination method, as described by Kwatra et al.[7]
Ethical approval 
Ethical approval for the study was obtained from the University of 
Pretoria Research Ethics Committee (ref. no. 393/2013). All study 
participants signed informed consent forms on recruitment into the 
study.
Results
Antimicrobial susceptibility testing showed that 69 (100%) isolates 
were susceptible to penicillin (MIC range 0.032 - 0.125 µg/mL) (Table 1). 
All isolates were susceptible to vancomycin, with 13 (18%) isolates 
having an MIC at the breakpoint (1.0 μg/mL) (MIC range 0.38 - 
1.00 µg/mL). Sixty (83%) isolates were sensitive to erythromycin, 
8 (11%) were intermediate and 1 (1%) was resistant (MIC range 0.094 
- 3.000 µg/mL). The erythromycin intermediate isolates belonged to 
serotypes Ia (n=3), III (n=2), IV (n=1) and V (n=2). 
Thirty (42%) isolates were found to be fully susceptible to 
clindamycin, while 40 (56%) were intermediate and no resistant 
isolates were detected (MIC range 0.19 - 0.75 µg/mL). The clindamycin 
intermediate isolates belonged to serotypes Ia (n=23), II (n=1), 
III (n=8), IV (n=1) and V (n=7). Only 3 (4%; serotypes Ia, III and 
V) of our isolates displayed a positive inducible MLSB (iMLSB) 
phenotype. All isolates were sensitive to levofloxacin (range 0.38 - 
1.50 µg/mL).
The serotype distribution of the 69 isolates was Ia (54%; n=37), 
III (20%; n=14), V (16%; n=11), II (6%; n=4), IV (3%; n=2) and Ib 
(1%; n=1). 
Discussion
The current study characterised the antimicrobial resistance patterns 
in GBS isolates from pregnant women. In this study, 69 (100%) 
isolates were fully susceptible to penicillin. In a recent Chinese study 
on colonising GBS isolates from pregnant women, 100% of isolates 
were sensitive to penicillin, ceftriaxone, linezolid and vancomycin.[10] 
Longtin et al.[11] described a case of GBS with reduced susceptibility 
to penicillin emerging after long-term suppressive oral penicillin 
therapy for a prosthetic joint infection.
All isolates in this study were susceptible to vancomycin. There is a 
paucity of data on vancomycin resistance in GBS isolates, with 2 case 
reports. These involved 2 patients with invasive GBS infection with 
significant comorbidities, including diabetes, hypertension, congestive 
cardiac failure, 1 patient with hypercholesterolaemia and 1 patient 
with end-stage renal disease, obesity, cor pulmonale and chronic 
osteomyelitis.[12] Only 1 of these patients had previous prolonged 
exposure to vancomycin. Both isolates were characterised as belonging 
to serotype II. In both cases the vancomycin MIC was 4 µg/mL. 
Macrolides are often regarded as an alternative therapy for 
penicillin-sensitive patients to treat GBS infections; however, 
Table 1. Antimicrobial susceptibility of 69 group B streptococcus isolates to 5 antimicrobial agents
Antimicrobial agent MIC50, µg/mL MIC90, µg/mL Range, µg/mL
Penicillin 0.047 0.064 0.032 - 0.125
Erythromycin 0.19 0.25 0.094 - 3.000
Clindamycin 0.25 0.5 0.19 - 0.75
Vancomycin 0.75 0.5 0.38 - 1.00
Levofloxacin 0.5 0.75 0.38 - 1.50
MIC = minimum inhibitory concentration.
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resistance to macrolides has increased during recent years in several 
countries, with geographical variations.[13] In the Japanese study by 
Matsubara et al.,[14] researchers found much lower rates of resistance 
to erythromycin and clindamycin (3% and 1%, respectively). In a 
Malaysian study, 23.3% of isolates were resistant to erythromycin and 
17.5% to clindamycin.[15] The prevalence of resistance among invasive 
GBS isolates in the USA ranged from 25% to 32% for erythromycin 
and from 13% to 20% for clindamycin in reports published during 
2006 - 2009.[2] Our data suggest a lower level of resistance to these 
two agents than those observed in the USA and are closer to the 
Japanese data.[2,14]
The CLSI recommends MLSB for beta-haemolytic streptococci, 
which tests for inducible clindamycin resistance. It was found to 
be the main mechanism of resistance in GBS isolated from the 
vagina, gastric fluid and ear specimens in a Tunisian study.[13] This 
phenomenon was noted in only 3 (4%) of our isolates. The serotype 
distribution of these isolates was Ia, III and V. 
All isolates in this study were susceptible to levofloxacin. However, 
reports of fluoroquinolone-resistant GBS strains have emerged in the 
past decade, especially in Asia, including China, Japan and Korea.[16] 
A study by Wu et al.[16] confirmed that respiratory samples and elderly 
patients are two independent risk factors associated with levofloxacin 
resistance in GBS. The study also found that levofloxacin-resistant 
GBS isolates belonged mainly to the ST19/serotype III serogroup.[16]
Information regarding serotype distribution of GBS strains could 
guide the development of vaccine candidates. Vaccinating pregnant 
women against GBS may protect infants from developing invasive 
GBS disease. Universal screening programmes for maternal GBS 
colonisation followed by IAP in colonised mothers have been 
shown to decrease the incidence of EOD.[2] However, it is thought 
to have a minimal role in the prevention of LOD.[1] GBS maternal 
vaccination has the potential to decrease EOD, as well as have an 
impact on LOD.[1]
This study showed that serotypes Ia (54%), III (20%) and V (16%) 
were predominant, which is in accordance with results of other studies 
conducted among pregnant women in SA.[4] Serotypes Ia and III 
together accounted for 74% of the colonised population in our study, 
while the 3 dominant serotypes accounted for 90% of all cases. These 
results are in keeping with those of another SA study that showed 
that serotype III is the most common cause of EOD, accounting for 
41.4% of all cases, while serotype Ia accounted for 34.7% of cases.[4] 
The majority of invasive disease was caused by serotypes Ia, III and 
V.[4] These 3 serotypes are included in a pentavalent polysaccharide 
protein conjugate vaccine currently being developed (phase I trial).[17]
Study limitations
The study included isolates from patients seen at a single centre. A 
further limitation was that we only included rectovaginal colonising 
isolates and no invasive isolates from neonates. The small sample size 
is a further limitation of the study.
Conclusions
GBS isolates remain susceptible to penicillin and vancomycin; however, 
surveillance for resistance needs to be ongoing. Macrolides should only 
be used when susceptibility results are available, as significant rates of 
intermediate resistance have been detected in these isolates. Ninety 
percent of colonising isolates belong to 3 serotypes, i.e. Ia, III and V. 
The findings in this study confirm that most of the serotypes in our 
area will be covered by the current vaccines that are being developed. 
In view of the small study sample size, we recommend future studies 
looking into GBS serotype data in SA. 
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